KZR
HEALTHCAREKezar Life Sciences Inc
$7.38+0.04 (+0.54%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KZR Today?
No stock-specific AI insight has been generated for KZR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.53$7.55
$7.38
Fundamentals
Market Cap$55M
P/E Ratio—
EPS$-7.66
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume133K
Avg Volume (10D)—
Shares Outstanding7.4M
KZR News
14 articles- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value RightYahoo Finance·Mar 30, 2026
- Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life SciencesYahoo Finance·Mar 12, 2026
- Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune HepatitisYahoo Finance·Jan 9, 2026
- Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Jan 5, 2026
- Kezar Life Sciences Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 12, 2025
- Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025Yahoo Finance·Nov 7, 2025
- Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic AlternativesYahoo Finance·Oct 16, 2025
- All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to BuyYahoo Finance·Sep 17, 2025
- Kezar Life Sciences to Participate in Two Upcoming Investor ConferencesYahoo Finance·Aug 28, 2025
- Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Aug 13, 2025
- Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune HepatitisYahoo Finance·Jul 15, 2025
- Kezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2025
- Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·May 27, 2025
- Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·May 13, 2025
All 14 articles loaded
Price Data
Open$7.34
Previous Close$7.34
Day High$7.39
Day Low$7.30
52 Week High$7.55
52 Week Low$3.53
52-Week Range
$3.53$7.55
$7.38
Fundamentals
Market Cap$55M
P/E Ratio—
EPS$-7.66
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume133K
Avg Volume (10D)—
Shares Outstanding7.4M
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—